Results 51 to 60 of about 2,498 (139)

Systemic medications associate with surgically treated cataract among adults over 50 years in Finland

open access: yesActa Ophthalmologica, Volume 104, Issue 6, Page e630-e647, September 2026.
Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen   +3 more
wiley   +1 more source

Hiperprolactinemia em pacientes femininas: estudo de seis casos. [PDF]

open access: yes, 1999
Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde, Departamento de Tocoginecologia, Curso de Medicina, Florianópolis ...
Martins, Angelo Francisco
core  

Cabergoline induced upregulation of glutamate transporters.

open access: yes, 2014
(A) Pretreatment with cabergoline reduced H2O2-induced extracellular glutamate accumulation. Pretreatment with cabergoline was performed 24 hours before H2O2 application.
Naoki Adachi (575911)   +7 more
core   +1 more source

Cabergoline for levodopa-induced complications in Parkinson\u27s disease

open access: yes
BACKGROUND: Long term levodopa therapy in Parkinson\u27s disease is associated with the development of motor complications including abnormal involuntary movements and a shortening response to each dose (wearing off phenomenon).
Deane KH; Clarke CE
core   +5 more sources

A possible role of GDNF expression by which cabergoline use affects corpus callosum

open access: yesJournal of Pediatric and Neonatal Individualized Medicine, 2018
A variety of malformations have been associated with cabergoline use during gestation. Recently we had a preterm male infant referred to our Neonatal Intensive Care Unit diagnosed with corpus callosum agenesis confirmed by brain ultrasound and brain ...
Georgios Mitsiakos, Anastasia Gkampeta
doaj   +1 more source

Cabergoline reduces 3-methoxytyramine in a SDHC patient with metastatic paraganglioma and prolactinoma

open access: yesEndocrinology, Diabetes & Metabolism Case Reports, 2021
We observed a novel therapeutic response with cabergoline in a male patient with a dopamine-secreting head and neck paraganglioma (HNPGL), macroprolactinoma and germline succinate dehydrogenase C mutation (SDHC).
Ziad Hussein   +3 more
doaj   +1 more source

ACTH suppression and adverse effects of cabergoline in horses with pituitary pars intermedia dysfunction

open access: yesEquine Veterinary Education, Volume 38, Issue 9, Page e622-e630, September 2026.
Summary Background The diagnosis and management of pituitary pars intermedia dysfunction (PPID) in horses includes evaluating abnormal plasma concentrations of adrenocorticotrophic hormone (ACTH). Treatment commonly includes the oral dopamine agonist pergolide mesylate, which suppresses the pathologic overproduction of ACTH.
A. Bracken   +5 more
wiley   +1 more source

Macroprolactinoma with progressive resistance to high-dose cabergoline

open access: yes, 2006
Introduction True resistance to cabergoline in patients with hyperprolactinaemia has only rarely been reported. We describe a patient with macroprolactinoma who initially responded to cabergoline, but then developed a progressive increase in PRL levels ...
Ball SG   +5 more
core   +5 more sources

Effects of feed energy density, daily milking frequency, and a single injection of cabergoline on behavior and welfare in dairy cows at dry-off

open access: yesJournal of Dairy Science, 2023
: Drying off dairy cows may challenge animal welfare due to high milk yields. A total of 111 loose-housed Holstein cows yielding >15 kg/d of milk were included in a 2 × 2 × 2 factorial design during dry-off to investigate the effects of reduced feeding ...
Margit Bak Jensen   +4 more
doaj   +1 more source

The Serotonin 2B (5‐HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 345-356, August 2026.
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy